The Emerging Role of miR-375 in Cancer

被引:234
作者
Yan, Jun-Wei [1 ]
Lin, Ju-Sheng [1 ]
He, Xing-Xing [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Liver Dis, Wuhan 430074, Peoples R China
基金
中国国家自然科学基金;
关键词
miR-375; tumor suppressor; microRNA; cancer; SQUAMOUS-CELL CARCINOMA; ELEVATED GENE-1 AEG-1; PROTEIN-KINASE B; CIRCULATING MICRORNAS; GASTRIC-CANCER; DOWN-REGULATION; HEPATOCELLULAR-CARCINOMA; EXPRESSION; BIOMARKERS; HEAD;
D O I
10.1002/ijc.28563
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs (miRNAs) are evolutionarily conserved, small noncoding RNAs that are believed to play fundamental roles in various biological processes through regulation of gene expression at the level of posttranscription. MiR-375 was first identified as a pancreatic islet-specific miRNA regulating insulin secretion. However, further study revealed that miR-375 is a multifunctional miRNA participating in pancreatic islet development, glucose homeostasis, mucosal immunity, lung surfactant secretion and more importantly, tumorigenesis. Recently, miR-375 has been found significantly downregulated in multiple types of cancer, and suppresses core hallmarks of cancer by targeting several important oncogenes like AEG-1, YAP1, IGF1R and PDK1. The alteration of miR-375 in cancer is caused by a variety of mechanisms, including the dysregulation of transcription factors, aberrant promoter methylation and so on. Reduced expression of miR-375 in tissue or circulation may indicate the presence of neoplasia as well as a poor prognosis of many malignant cancers. Moreover, miR-375 stands for a promising direction for developing targeted therapies due to its capacity to inhibit tumor cell growth in vitro and in vivo. Here, we summarize the present understanding of the tumor suppressive role of miR-375 in cancer progression; the mechanisms underlying the dysregulation of miR-375; the potential use of miR-375 in prognosis and diagnosis and the therapeutic prospects of miR-375 in cancer.
引用
收藏
页码:1011 / 1018
页数:8
相关论文
共 98 条
[1]   Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha [J].
Alessi, DR ;
James, SR ;
Downes, CP ;
Holmes, AB ;
Gaffney, PRJ ;
Reese, CB ;
Cohen, P .
CURRENT BIOLOGY, 1997, 7 (04) :261-269
[2]   Mechanism of activation of protein kinase B by insulin and IGF-1 [J].
Alessi, DR ;
Andjelkovic, M ;
Caudwell, B ;
Cron, P ;
Morrice, N ;
Cohen, P ;
Hemmings, BA .
EMBO JOURNAL, 1996, 15 (23) :6541-6551
[3]   Head and neck cancer [J].
Argiris, Athanassios ;
Karamouzis, Michalis V. ;
Raben, David ;
Ferris, Robert L. .
LANCET, 2008, 371 (9625) :1695-1709
[4]   MicroRNA Expression Ratio Is Predictive of Head and Neck Squamous Cell Carcinoma [J].
Avissar, Michele ;
Christensen, Brock C. ;
Kelsey, Karl T. ;
Marsit, Carmen J. .
CLINICAL CANCER RESEARCH, 2009, 15 (08) :2850-2855
[5]   The Promoter of the pri-miR-375 Gene Directs Expression Selectively to the Endocrine Pancreas [J].
Avnit-Sagi, Tali ;
Kantorovich, Lia ;
Kredo-Russo, Sharon ;
Hornstein, Eran ;
Walker, Michael D. .
PLOS ONE, 2009, 4 (04)
[6]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[7]   Serum microRNAs as non-invasive biomarkers for cancer [J].
Brase, Jan C. ;
Wuttig, Daniela ;
Kuner, Ruprecht ;
Sueltmann, Holger .
MOLECULAR CANCER, 2010, 9
[8]   Changes in circulating microRNA levels associated with prostate cancer [J].
Bryant, R. J. ;
Pawlowski, T. ;
Catto, J. W. F. ;
Marsden, G. ;
Vessella, R. L. ;
Rhees, B. ;
Kuslich, C. ;
Visakorpi, T. ;
Hamdy, F. C. .
BRITISH JOURNAL OF CANCER, 2012, 106 (04) :768-774
[9]   Regulation of cancer cell metabolism [J].
Cairns, Rob A. ;
Harris, Isaac S. ;
Mak, Tak W. .
NATURE REVIEWS CANCER, 2011, 11 (02) :85-95
[10]   Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma [J].
Chang, Chongwang ;
Shi, Hangyu ;
Wang, Chao ;
Wang, Jing ;
Geng, Ning ;
Jiang, Xue ;
Wang, Xuelian .
NEUROSCIENCE LETTERS, 2012, 531 (02) :204-208